mRESVIA

Active
Moderna
Moderna

Overview

mRNA vaccine (mRNA-1345) against respiratory syncytial virus (RSV) - the first mRNA vaccine approved for a disease other than COVID-19, and a key pillar of Moderna's expanding respiratory franchise.

FDA-approved May 2024 for adults 60+, with a US label expansion to at-risk adults 18-59 in June 2025. The European Commission separately extended the EU label to at-risk adults 18-59 in 2026. Small but growing sales as Moderna builds a multi-product respiratory portfolio.

Key Specs

FDA Approval

May 2024 (60+); expanded to at-risk 18-59 Jun 2025

Indication

RSV: adults 60+, plus at-risk adults 18-59 (US and EU)